Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Biolight Meditech and D.A. Diagnostics Debut on ChiNext Exchange

publication date: Jul 20, 2011
Two China biopharmas have completed IPOs on Shenzhen’s ChiNext Exchange. Guangdong Biolight Meditech, a medical device maker whose products include patient monitors and central monitoring systems, raised 262.5 million RMB ($40.6 million). Zhejiang D.A. Diagnostics, a third-party diagnostic services and diagnostic products distributor, raised 301 million RMB ($46.6 million). Both offerings, though modest in size, turned out to be very positive for the IPO investors. More details....

Stock Symbols: (SHE: 300246) (SHE: 300245)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital